SYRS News and Press, Syros Pharmaceuticals Inc. From 11/04/20

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and p...

Syros Pharmaceuticals (SYRS) has announced initial safety, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) data from dose-escalating part of its Phase 1 trial of SY-5609 in patients with select solid tumors. Data are being presented at the 32nd EORTC-NCI-AACR Symposium.SY-5...

Early Dose-Escalation Data Demonstrate Proof of Mechanism and Support Ongoing Development of SY-5609 for Difficult-to-Treat Cancers On Track to Report Additional Data, including Clinical Activity Data, in Mid-2021 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing dose escalation portion of its Phase 1 clinical trial of SY-5609, its highly selective and potent oral c...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Cantor Virtual Global Healthcare Conference. Details are as foll...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S. Gail Eckhardt, M.D., to the Company’s Board of Directors. Dr. Eckhardt is a highly respected oncologist and a leader in targeted on...

Gainers:  PolyMet Mining (NYSEMKT: PLM ) +83% . More news on: PolyMet Mining Corp., VivoPower International PLC, FBL Financial Group, Inc., Stocks on the move, , Read more ...

Syros Pharmaceuticals, Inc. (SYRS) Q2 2020 Results Conference Call August 06, 2020 08:30 AM ET Company Participants Naomi Aoki - IR Nancy Simonian - CEO Joe Ferra - CFO David Roth - CMO Conference Call Participants Phil Nadeau - Cowen and Company Ted Tenthoff - Piper Sa...

Syros Pharmaceuticals (NASDAQ: SYRS ) : Q2 GAAP EPS of -$0.38 beats by $0.02 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...